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Abstract 
Introduction: Although hyperthyroidism is characterised by female predominance, its presence may lead to the development of numer-
ous complications in both sexes. This study was aimed at investigating sexual function and depressive symptoms in men with overt 
hyperthyroidism of autoimmune and non-autoimmune origin.
Material and methods: The study population consisted of three age-matched groups: men with overt hyperthyroidism and Graves’ dis-
ease (group A; n = 20), men with overt hyperthyroidism and toxic multinodular goitre or toxic adenoma (group B; n = 21), and men with 
normal thyroid function (group C; n = 23). As well as measuring serum hormone levels and antibody titres, and determining calculated 
parameters of thyroid homeostasis, all included patients filled in questionnaires evaluating sexual function (International Index of Erectile 
Function-15: IIEF-15) and assessing the presence and severity of depressive symptoms (Beck Depression Inventory-Second Edition – BDI-II).
Results: Compared with control subjects, men with overt hyperthyroidism obtained lower scores for erectile function, intercourse sat-
isfaction, orgasmic function and overall satisfaction. Scores for erectile function, orgasmic function, and sexual desire differed between 
both groups of men with thyroid hyperfunction and inversely correlated with thyrotropin receptor antibody titres. The BDI-II score was 
higher in patients with Graves’ disease than in men with normal thyroid function.
Conclusions: The obtained results indicate that overt hyperthyroidism in men causes multidimensional impairment of sexual function, 
which is particularly pronounced if excessive hormone production results from Graves’ disease. (Endokrynol Pol 2019; 70 (1): 64–71)
Key words: depressive symptoms; Graves’ disease; hyperthyroidism; sexual functioning; thyroid nodules
Streszczenie
Wprowadzenie: Chociaż nadczynność tarczycy występuje częściej u kobiet niż mężczyzn, obecność tego schorzenia powodować może 
wystąpienie licznych powikłań u obu płci. Celem badania była ocena funkcjonowania seksualnego i objawów depresyjnych u mężczyzn 
z jawną nadczynnością tarczycy o podłożu autoimmunologicznym i nieautoimmunologicznym.
Materiał i metody: Badaną populację stanowiły trzy grupy mężczyzn w porównywalnym wieku: mężczyźni z jawną nadczynnością 
tarczycy na tle choroby Gravesa i Basedowa (grupa A, n = 20), mężczyźni z jawną nadczynnością tarczycy spowodowaną wolem wie-
loguzkowym lub pojedynczym gruczolakiem (grupa B, n = 21) oraz mężczyźni z prawidłową funkcją hormonalną tarczycy (grupa C, 
n = 23). Poza oceną stężeń hormonów w surowicy, zbadaniem miana przeciwciał i wyliczeniem wartości strukturalnych wskaźników 
homeostazy tarczycowej, uczestnicy badania wypełnili kwestionariusze oceniające funkcjonowanie seksualne (IIEF-15) oraz obecność 
i nasilenie objawów depresyjnych (BDI-II).
Wyniki: W porównaniu z grupą kontrolną mężczyźni z jawną nadczynnością tarczycy charakteryzowali się niższą punktacją w zakresie: 
funkcji erekcyjnej, satysfakcji ze stosunku, jakości orgazmu i całkowitej satysfakcji seksualnej. Punktacja w zakresie: funkcji erekcyjnej, 
jakości orgazmu i pożądania różniła się między obiema grupami mężczyzn z nadczynnością tarczycy, wykazując ujemną korelację z mia-
nem przeciwciał przeciwko receptorowi dla TSH. Globalna wartość wskaźnika BDI-II była wyższa u osób z chorobą Gravesa-Basedowa 
w porównaniu z grupą kontrolną.
Wnioski: Uzyskane wyniki wskazują, że jawna nadczynność tarczycy powoduje wielokierunkowe zaburzenia funkcjonowania seksualnego 
u mężczyzn, szczególnie silnie wyrażone w przypadku nadczynności spowodowanej przez chorobę Gravesa i Basedowa. (Endokrynol 
Pol 2019; 70 (1): 64–71)
Słowa kluczowe: objawy depresyjne; choroba Gravesa i Basedowa; nadczynność tarczycy; funkcjonowanie seksualne; guzki tarczycy
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men with frank hyperthyroidism of either autoimmune 
(Graves’ disease) or non-autoimmune (thyroid nodular 
disease) origin and a matched group of men with intact 
hypothalamic-pituitary-thyroid axis activity.
Material and methods
Study population
The participants of the study were recruited among 
adult men (20–60 years old) with symptoms or signs 
suggestive of hyperthyroidism (weight loss, tachycar-
dia, intolerance to heat, excessive sweating, or diar-
rhoea). The patients were eligible for the study if they 
met the following criteria of overt hyperthyroidism: 
serum thyrotropin levels below 0.1 mIU/L, serum free 
thyroxine levels above 23 pmol/L, and/or free triiodo-
thyronine levels above 6.5 pmol/L. Based on serum 
titres of thyrotropin receptor antibodies (TRAb) and 
thyroid ultrasound imaging characteristics, they were 
enrolled into one of two groups: group A including 
20 patients with Graves’ disease (TRAb titres above 
1.8 U/L) or group B including 21 men with either toxic 
multinodular goitre (n = 11) or toxic adenoma (n = 10). 
The control group consisted of 23 men screened for the 
presence of hyperthyroidism, in whom thyrotropin and 
free thyroid hormone levels were within the reference 
range. 
The subjects were excluded if they met at least one 
of the following criteria: the presence of both TRAb and 
thyroid nodules, other forms of overt hyperthyroidism; 
subclinical hyperthyroidism; euthyroid sick syndrome; 
thyroid cancer; type 1 or type 2 diabetes; hyperpro-
lactinaemia; hypogonadism; osteoporosis; prostate, 
cardiovascular, neurologic, or psychiatric disorders; 
impaired renal or hepatic function; acute or chronic 
infection; abnormal rectal bleeding; developmental or 
acquired anomalies of the male reproductive system; 
a past history of myocardial infarction or acute cerebro-
vascular events; a past history of total or transurethral 
prostatectomy; a past history of major pelvic surgery 
or of other operations that might have affected sexual 
function; sexual inactivity; and any pharmacotherapy.
All subjects gave written, informed consent to 
participate in the study, and the study protocol was 
approved by the Local Ethics Committee.
Laboratory assays
Venous blood samples were taken 12 h after the last 
meal in a quiet, temperature-controlled room (24–25°C). 
To avoid possible circadian fluctuations in the param-
eters studied, samples were drawn during constant 
daily hours (between 8.00 and 9.00 a.m.), and to mi-
nimise analytical errors, all assays were performed in 
duplicate. Before submission of our manuscript, we 
Introduction 
Hyperthyroidism, defined as the excess production and 
release of thyroid hormone by the thyroid gland, is one 
of the most common endocrine disorders in developed 
countries [1]. In the United States, the prevalence of 
hyperthyroidism is approximately 1.2% [2], and in Eu-
rope 0.8% [3]. Thyroid hyperfunction is caused mainly 
by Graves’ disease, toxic multinodular goitre, and toxic 
adenoma [4, 5]. Despite a clear female preponderance, 
men may also suffer from this disorder. In Europe, the 
prevalence of overt and subclinical hyperthyroidism in 
men is estimated at 0.48% and 1.97%, respectively, while 
the incidence rate of thyroid hyperfunction is calcu-
lated to be 72.48 per 100,000 [3]. Irrespective of gender, 
a disproportionate amount of thyroid hormone leads 
to an accelerated metabolic state, causing significant 
morbidity and mortality [6]. 
The results of some studies conducted to date sug-
gest that thyroid disorders may have an unfavourable 
effect on sexual functioning in men. The most char-
acteristic abnormality related to this clinical entity is 
acquired premature ejaculation [7–9]. Hyperthyroidism 
is also associated with the presence of erectile dysfunc-
tion, including its severe form [9–12]. This relationship 
did not change after adjusting for age, which suggests 
that inappropriate thyroid hormone levels are probably 
more important than age in inducing erectile dysfunc-
tion [11, 12]. Unlike hypothyroidism, the association 
between hyperthyroidism and impaired erectile func-
tioning was also found to be independent of other 
potential confounders including age, body mass index, 
blood pressure, other hormones, and serum lipids [11]. 
Interestingly, both the risk of premature ejaculation and 
erectile dysfunction was reduced by treating the under-
lying disease [8–10]. Thyroid overactivity, although to 
a lesser extent than hypothyroidism, may also predis-
pose to the development of hypoactive sexual desire 
[9]. Finally, thyroid hormone overproduction induces 
a decrease in total seminal volume and total sperm 
count, increases the percentage of dead sperm, and 
disturbs progressive mobility, lineal progressive motil-
ity, and sperm morphology [13]. Unfortunately, the 
clinical significance of these findings is seriously limited 
by methodological problems, the fact that participants 
knew their thyroid status, and by analysing only some 
aspects of men’s sexual response.
Recently we have shown that the impact of subclini-
cal thyroid hypofunction on sexual functioning and on 
mood in women was stronger if hypothyroidism was 
secondary to Hashimoto’s thyroiditis [14]. Because of 
the lack of similar data in hyperthyroidism, in the cur-
rent study we have compared various aspects of male 
sexual functioning and depressive symptoms between 
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also retrospectively measured serum levels of free tes-
tosterone and prolactin in 12 randomly selected stored 
serum samples from each study group. All tests were 
performed in blinded fashion by persons unaware of 
patient characteristics. Serum levels of thyrotropin, 
free thyroxine, free triiodothyronine, and prolactin, as 
well as titres of thyroid peroxidase antibodies (TPOAb) 
were determined by direct chemiluminescence using 
acridinium ester technology (ADVIA Centaur XP Immu-
noassay System, Siemens Healthcare Diagnostics, Mu-
nich, Germany). Circulating levels of free testosterone 
were determined by enzyme-linked immunosorbent 
assay using a EUROIMMUN analyser I (Euroimmun, 
Wrocław, Poland). Titres of TRAb were measured by 
immunoassay with chemiluminescent detection (Im-
mulite 2000XPi, Siemens Healthcare, Warsaw, Poland). 
Parameters of thyroid homeostasis: Jostel’s thyrotropin, 
structure parameter inference approach (SPINA)-
GT and SPINA-GD indices were calculated using 
SPINA-Thyr 4.0.1 for Windows software according to 
the formulas described previously [15–17]. 
Questionnaires
Immediately after collecting blood samples and the 
ultrasound, the participants were asked to complete 
three questionnaires. The first questionnaire assessed 
their demographic characteristics, smoking, physical 
activity, education, occupation, stress exposure, number 
of sexual partners, and number and duration of mar-
riages. The second questionnaire (the International 
Index of Sexual Function-15 — IIEF-15 for heterosexual 
men) evaluated sexual functioning, while the third one 
(Beck Depression Inventory-Second Edition - BDI-II) 
evaluated depressive symptoms. 
IIEF-15 is self-administered questionnaire, com-
posed of 15 items, regarded as a reliable, cross-cul-
turally valid, and psychometrically sound measure 
of male sexual function [18, 19]. The items evaluate 
five relevant domains of male sexual functioning in 
the previous four weeks: erectile function (questions 
1–5 and 15), intercourse satisfaction (questions 6–8), 
orgasmic function (questions 9 and 10), sexual desire 
(questions 11 and 12), and overall satisfaction (ques-
tions 13 and 14). Questions are scored on a five-point 
or six-point Likert scale, with responses ranging from 
0 to 5 or 1 to 5. Minimum scores were: 0 for intercourse 
satisfaction and orgasmic function, 1 for erectile func-
tion, and 2 for sexual desire and overall satisfaction. 
Maximum scores were: 10 for orgasmic function, 
sexual desire and overall satisfaction, 15 for intercourse 
satisfaction, and 30 for erectile function. The severity of 
erectile dysfunction was classified into five categories: 
no erectile dysfunction (score 26 to 30), mild erectile 
dysfunction (score 22 to 25), mild to moderate erectile 
dysfunction (score 17 to 21), moderate erectile dysfunc-
tion (score 11 to 16), and severe erectile dysfunction 
(score 6 to 10) [18–20].
BDI-II is a self-rating scale with 21 items, which are 
focused on depression symptoms: affective, motiva-
tional, cognitive, and physiological during the previ-
ous two weeks [21–23]. The items have been adjusted 
to measure depressive symptoms corresponding with 
the diagnostic criteria for depressive disorders outlined 
in the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition [24]. Each item is rated on 
a four-point scale from 0 (not present) to 3 (severe). 
The overall score ranges from 0 to 63, with higher val-
ues indicating more severe depressive symptoms. The 
BDI-II score from 14 to 19 points is interpreted as mild 
depression, from 20 to 28 as moderate depression, and 
from 29 to 63 as severe depression [21–23].
Statistical analysis
Because of skewed distributions, all parameters were 
natural-log transformed to meet the assumptions of 
parametric tests. Between-group comparisons were 
performed using analysis of covariance followed by 
Bonferroni post hoc tests after consideration of age, 
smoking, body mass index, waist circumference, marital 
status, education, occupational activity, type of work, 
profession, physical activity, and stress exposure, as 
well as blood pressure as potential confounders. The 
χ2 test was employed to compare the proportional data. 
Correlations were assessed using the Pearson partial 
correlation coefficient (r). Statistical significance was 
assumed at p < 0.05. 
Results
General characteristics of the study groups
There were no differences between the study groups 
in age, smoking (the number of cigarettes and duration 
of smoking), education, occupational activity, type of 
work, number of sexual partners, number and duration 
of marriages, and stress exposure. Men with thyroid 
hyperfunction differed from men with normal thyroid 
function in body mass index, physical activity, and 
blood pressure (Tab. I). 
As expected, there were differences between men 
with hyperthyroidism and subjects with normal thyroid 
function in serum levels of thyrotropin and free thy-
roid hormones, as well as between men with Graves’ 
disease and the remaining groups of patients in serum 
titres of TRAb and TPOAb. Jostel’s thyrotropin index 
was lower, while the SPINA-GT and SPINA-GD indices 
were higher in groups A and B than in group C. Levels 
of free triiodothyronine and the SPINA-GD index were 
higher in group A than in group B. Serum levels of free 
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testosterone were lower in group A than in groups B 
and C (Tab. II).
Assessment of sexual function 
The study groups differed in the percentage of pa-
tients with erectile dysfunction. In group A, mild, mild 
to moderate, moderate, and severe erectile dysfunction 
was found in three (15%), six (30%), six (30%), three 
(15%), and two subjects (10%), respectively. In group 
B, six men (29%) had mild, four men (19%) had mild 
to moderate, two men (10%) had moderate, and one 
man (5%) had severe erectile dysfunction. In group 
C, five subjects (22%) had mild while one man (4%) 
had mild to moderate erectile dysfunction. Compared 
with group C, men with overt hyperthyroidism ob-
tained lower scores for erectile function, intercourse 
satisfaction, orgasmic function, and overall satisfac-
tion. Scores for erectile function, orgasmic function, 
and desire were lower in group A than in group B 
(Tab. III).
Assessment of depressive symptoms
The overall BDI-II score was higher in group A than 
in group C, and was insignificantly higher in group 
Table II. Serum hormone levels, antibody titres, and thyroid function tests in the study population
Tabela II. Stężenie hormonów, miano przeciwciał i strukturalne wskaźniki homeostazy tarczycowej uczestników badania
Variable Group A1 Group B2 Group C3
Thyrotropin [mIU/L; mean (SD)]  0.016 (0.012)d 0.018 (0.016)d 1.345 (0.945)
Free thyroxine [pmol/L; mean (SD)] 37.5 (6.7)d 38.2 (6.2)d 16.0 (3.4)
Free triiodothyronine [pmol/L; mean (SD)] 18.7 (6.0)b,d 12.8 (3.9)d 4.2 (1.2) 
Thyrotropin receptor antibodies [U/L; mean (SD)] 6.2 (2.0)b,d 0.1 (0.1) 0.1 (0.1) 
Thyroid peroxidase antibodies [U/mL; mean (SD)] 205 (194)b,d 14 (9) 15 (10)
Jostel’s thyrotropin index [mean (SD)] 0.9 (0.3)d 1.1 (0.3)d 2.4 (0.4)
SPINA-GT index [pmol/s; mean (SD)] 492.12 (85.65)d 445.92 (68.94)d 3.70 (0.82)
SPINA-GD index [nmol/s; mean (SD)] 46.11 (7.81)b,d 30.98 (5.74)d 24.27 (3.28)
Prolactin [µg/L; mean (SD) 10 (4) 10 (5) 11 (6)
Free testosterone [pmol/L; mean (SD)]4 270 (59)a,c 328 (82) 316 (68)
1Men with overt hyperthyroidism and Graves’ disease; 2Men with overt hyperthyroidism and toxic multinodular goitre or toxic adenoma; 3Men with normal thyroid 
function; 4Data of 12 men from each group; ap < 0.05, bp < 0.001 vs. group B; cp < 0.05, dp < 0.001 vs. group C; SD — standard deviation
Table I. Sociodemographic characteristics of the study population
Tabela I. Wyjściowa charakterystyka uczestników badania
Group A1 Group B2 Group C3
Number of patients 20 21 23
Age [years; mean (SD)] 47 (8) 49 (7) 50 (7)
Body mass index [kg/m2; mean (SD)] 21.8 (3.8)d 22.0 (3.5)d 26.7 (4.9)
Smokers (%)/Number of cigarettes a day [n; mean (SD)]/ 
/Duration of smoking [years, mean (SD)]
35/15 (8)/20 (10) 29/14 (9)/22 (12) 30/14 (7)/23(11)
Physical activity: total/once a week/several times a week/ 
/once a month (%)
35/15/0/20c 38/24/0/13c 100/48/43/9
Primary or vocational/secondary/university education (%) 20/40/40 19/43/38 22/39/39
Occupational activity/blue-collar/white-collar/pink-collar workers (%) 100/45/55/0 95/43/52/0 100/43/57/0
Number of sexual partners [n; mean (SD)] 3.1 (1.1) 3.0 (1.0) 2.8 (1.0)
Number of marriages [n; mean (SD)]/duration of marriages  
[months; years (SD)]
1.4 (0.7)/18 (7) 1.4 (0.8)/19 (8) 1.3 (0.8)/20 (9)
Stress exposure [%, mean (SD)] 80 76 74
Systolic blood pressure [mmHg; mean (SD)] 137 (12)b 135 (12)a 127 (10)
Diastolic blood pressure [mmHg; mean (SD)] 75 (7)c 77 (8)b 84 (6)
1Men with overt hyperthyroidism and Graves’ disease; 2Men with overt hyperthyroidism and toxic multinodular goitre or toxic adenoma; 3Men with normal thyroid 
function; ap < 0.05, bp < 0.01, cp < 0.001 vs. group B; dp < 0.001 vs. group C; SD — standard deviation
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A than in group B (p = 0.092) and in group B than in 
group C (p = 0.055). The percentage of men with total 
and mild depressive symptoms was higher in group 
A than in group C. The study groups did not differ in 
the percentage of patients with moderate and severe 
depressive symptoms (Tab. IV).
Correlations
In all study groups, erectile function, intercourse sat-
isfaction, orgasmic function, sexual desire, and overall 
satisfaction inversely correlated with the total BDI-II 
score (r values between –0.29 [p < 0.05] and –0.49 
[p < 0.001]; group B: r values between –0.26 [p < 0.05] 
and –0.47 [p < 0.001]; group C r values between –0.28 
[p < 0.05] and –0.42 [p < 0.001]). There were also 
positive correlations between sexual desire (r values 
between 0.40 [p < 0.001] and 0.51 [p < 0.001]), and, to 
a lesser extent, other domains of sexual functioning (r 
values between 0.23 [p < 0.05] and 0.35 [p < 0.01]), and 
free testosterone levels. In group A, erectile function, 
orgasmic function, and sexual desire negatively corre-
lated with serum titres of TRAb (r values between –0.32 
[p < 0.05] and –0.46 [p < 0.001]) or TPOAb (r values 
between –0.25 [p < 0.05] and –0.37 [p < 0.01]), while 
BDI-II score positively correlated with antibody titres 
(TRAb: r = 0.35, p < 0.01; TPOAb: r = 0.38, p < 0.001). 
In subjects with overt hyperthyroidism, erectile func-
tion, intercourse satisfaction, orgasmic function, sexual 
desire, and overall satisfaction positively correlated 
with serum levels of thyrotropin (group A: r values 
between 0.28 [p < 0.05] and 0.42 [p < 0.001]; group B: 
r values between 0.24 [p < 0.05] and 0.41 [p < 0.001]) and 
negatively with serum levels of free thyroid hormones, 
SPINA-GT index, and SPINA-GD index (group A: 
r values between –0.28 [p < 0.05] and –0.46 [p < 0.001]; 
group B: r values between –0.26 [p < 0.05] and –0.42 
[p < 0.001]). In all study groups, there were also cor-
relations (a) between the mean BDI-II score and the 
body mass index (r values between 0.31 [p < 0.05] and 
0.42 [p < 0.001]), (b) between the mean BDI-II score 
and physical activity (r values between –0.28 [p < 0.05] 
and –0.34 [p < 0.05]), and (c) between the mean BDI-II 
score and systolic blood pressure (r values between 0.26 
[p < 0.05] and 0.36 [p < 0.01]). No other correlations 
were found.
Discussion
This study has shown for the first time that clinically 
overt hyperthyroidism causes multidimensional im-
pairment of male sexual function, which is accompa-
nied by relatively mild depressive symptoms. A strong 
point of our study is that, because of strict inclusion 
and exclusion criteria, the population was a relatively 
Table III. Sexual function in the study population
Tabela III. Funkcjonowanie seksualne uczestników badania
Variable Group A1 Group B2 Group C3
Erectile function [mean (SD)] 18.9 (6.4)a, d 22.5 (4.8)c 26.3 (2.4)
Erectile dysfunction [%] 85a,d 62c 26
Intercourse satisfaction [mean (SD)] 11.6 (2.3)c 11.8 (2.1)b 13.2 (1.5)
Orgasmic function [mean (SD)] 6.9 (1.1)a, d 7.8 (1.3)c 8.8 (1.0)
Sexual desire [mean (SD)] 7.5 (1.4)a, b 8.4 (1.4) 8.2 (1.6)
Overall satisfaction [mean (SD)] 7.4 (1.4)c 7.7 (1.5)b 8.7 (1.5)
1Men with overt hyperthyroidism and Graves’ disease; 2men with overt hyperthyroidism and toxic multinodular goitre or toxic adenoma; 3Men with normal thyroid 
function; ap < 0.05 vs. group B, bp < 0.05, cp < 0.01, dp < 0.001 vs. group C; SD — standard deviation
Table IV. Depressive symptoms in the study population
Tabela IV. Objawy depresyjne uczestników badania
Variable Group A1 Group B2 Group C3
BDI-II score [mean (SD)] 12.3 (4.7)b 9.8 (4.9) 7.2 (3.8)
Depressive symptoms [n (%)] 8 (40)a 5 (24) 2 (9)
Mild symptoms [n (%)] 8 (40)a 5 (24) 2 (9)
Moderate symptoms [n (%)] 0 (0) 1 (6) 0 (0)
Severe symptoms [n (%)] 0 (0) 0 (0) 0 (0)
1Men with overt hyperthyroidism and Graves’ disease; 2Men with overt hyperthyroidism and toxic multinodular goitre or toxic adenoma; 3Men with normal thyroid 
function; ap < 0.01, bp < 0.001 vs. group C; SD — standard deviation
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homogeneous group of drug-naïve men. Moreover, 
differences between hyperthyroid and euthyroid men 
could not have been attributed to signs and symptoms 
experienced by the participants of the study because 
both individuals with hyperthyroidism and control 
subjects with normal thyroid function were selected 
from among men complaining of weight loss, tachy-
cardia, intolerance to heat, excessive sweating, and/or 
diarrhoea. Finally, in contrast to most conducted stud-
ies, at the time of filling in all questionnaires neither 
the participants nor the investigators knew the results 
of the laboratory examinations (blood sampling and 
subsequent diagnosis were performed at the same time 
as completing the questionnaires). This eliminated the 
possibility that the participants were aware of their 
thyroid status, which might have made the obtained 
results highly questionable.
We have found numerous correlations between vari-
ous aspects of male sexual functioning and thyrotropin 
levels, free thyroid hormone levels, and the SPINA-GT, 
estimating the maximum secretion rate of the thyroid 
gland under stimulated conditions [16, 17]. These find-
ings suggest the impact of excessive amounts of thy-
roid hormones on brain structures involved in sexual 
behaviour and feelings and on sexual organs. This 
effect may be partially direct because both human and 
animal smooth muscle cells isolated from corpus cav-
ernosum were found to express both types of thyroid 
hormone receptors (TRα and TRα) [25].
 Moreover, thyroid 
hormone excess reduced nitric oxide production in the 
penile corpus cavernosum [26], as well as impaired 
endothelium-dependent (and neurogenic) relaxation 
of corporal smooth muscle [27]. These mechanisms 
may contribute to the development of impotence in the 
study population. However, taking into account that the 
mentioned correlations were at most moderate, it seems 
that the effect of hyperthyroidism on sexual function 
is also indirectly mediated by other mechanisms. One 
of them may be the impact on synthesis, protein bind-
ing and metabolism of testosterone [28]. In line with 
this hypothesis, free testosterone levels, representing 
a biologically relevant fraction of this hormone [29], 
correlated with all domains of male sexual functioning 
evaluated in our study. The finding that this correlation 
was strongest for desire is in agreement with the fact 
that hormones play a greater role in regulating libido 
than in the regulation of other domains of human 
sexual response, assessed by IIEF-15 questionnaire [30]. 
Therefore, it is possible that relatively high testosterone 
levels in men with toxic multinodular goitre or toxic ad-
enoma might have reversed the direct negative impact 
of thyroid hormone overproduction on libido, explain-
ing why, unlike other domains, desire in this study 
group did not differ from that observed in the control 
subjects. On the other hand, the lack of analogical cor-
relations for prolactin, as well as its similar levels in all 
study groups, suggest that prolactin does not mediate 
the effect of hyperthyroidism on male sexual behaviour.
Another important finding of the study was that 
some sexual disturbances (and depressive symptoms) 
were more frequent and more severe in men with 
Graves’ disease than in nodular thyroid disease. The 
former one is an organ-specific autoimmune thyroid 
disease responsible for most cases of thyroid hormone 
overproduction in developed countries [31]. Interest-
ingly, the same relationship between the severity of 
sexual dysfunction and a disease causing hyperthy-
roidism was recently observed by our research team 
in women (Krysiak et al., unpublished observation). 
Worse sexual functioning in men with Graves’ disease 
than in men with nodular thyroid disease seems to 
be associated with differences in hormone produc-
tion and metabolism. In line with this explanation, 
patients with Graves’ disease were characterised by 
higher levels of triiodothyronine and a higher value 
of the SPINA-GD, reflecting deiodinase activity and 
thyroxine:triiodothyronine conversion efficiency [16, 
17], as well as by lower levels of free testosterone. How-
ever, differences in erectile function, orgasmic function 
and sexual desire may be also attributed to the effect of 
autoimmunity. According to this explanation, TRAb and 
TPOAb antibody titres correlated with domain scores 
for erectile function, orgasmic function, and desire, but 
not with domain scores for intercourse satisfaction and 
overall satisfaction, which were similar in patients with 
Graves’ disease and thyroid nodular disease. Also, the 
finding that even euthyroid patients with Hashimoto’s 
thyroiditis were characterised by disturbances in desire, 
lubrication, and sexual satisfaction [14], indicates that 
autoimmune thyroid disorders may make subjects more 
prone to sexual dysfunction. Because free testosterone 
correlated with triiodothyronine and the SPINA-GD, 
but not with antibody titres, statistically significant 
differences in its levels between men with Graves’ dis-
ease and men with thyroid nodular disease should be 
interpreted as secondary to thyroid hormone produc-
tion and peripheral metabolism rather than be directly 
related to autoimmune process.
Beyond sexual dysfunction, men with thyroid hy-
perfunction, particularly subjects with Graves’ disease, 
were characterised by mood disturbances. The obtained 
results are in agreement with findings of other authors 
[32], who observed a significantly higher symptom level 
of depression in women and men with Graves’ disease 
compared to patients with nodular goitre. The fact 
that the overall BDI-II score correlated with all domain 
scores of IIEF indicates that male sexual functioning 
and depressive symptoms are reciprocally related 
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but does not allow us to determine whether depres-
sive symptoms reflect sexual dysfunction or impaired 
sexual functioning plays a role in the development of 
these symptoms. The increased overall BDI-II score, 
as well as a higher percentage of men with total and 
mild depressive symptoms, may be associated with the 
proinflammatory state, characteristic for Graves’ disease 
[33], which seems to contribute to the development of 
depression [34]. In line with this hypothesis, TRAb and 
TPOAb titres in our study correlated with the BDI-II 
score. The remaining potential mechanisms implicated 
in this relationship include a direct effect of thyroid 
hormone excess on the limbic system, the impact of 
thyroid overactivity on adrenergic neurotransmission 
in the central nervous system, as well as the effect of 
hyperthyroidism on hypothalamic-pituitary-adrenal 
axis activity [35]. Moreover, as other correlations sug-
gest, the increased symptom level of depression in the 
investigated population of hyperthyroid men was also 
associated with the presence of other factors, including 
higher values of systolic blood pressure, reduced physi-
cal activity, and self-perception of weight.
There are some shortcomings that may limit the gen-
eralisability of our findings. The study groups included 
a relatively small number of patients, and therefore the 
results need to be confirmed in a larger population of 
patients. The study was carried out in the Upper Sile-
sia, which is a selenium-deficient [36] and, because of 
mandatory salt iodisation, iodine-sufficient [37] area. It 
remains unsolved whether the impact of thyroid over-
activity on sexual functioning and depressive symptoms 
is the same in men in whom selenium supply is suf-
ficient and/or iodine supply is insufficient. The study 
protocol does not allow us to conclude whether and 
to what extent male sexual functioning and mood are 
disturbed in subjects with subclinical hyperthyroidism, 
not included in our study. Finally, although the IIEF-15 
and BDI-II questionnaires are well-validated, their util-
ity is limited by subjectivity.
Conclusions
In conclusion, men with overt hyperthyroidism were 
characterised by disturbances in almost all aspects of 
male sexual functioning assessed by the IIEF ques-
tionnaire (erectile function, intercourse satisfaction, 
orgasmic function, and overall satisfaction) and by 
relatively small changes in mood. Individuals with 
Graves’ disease differed from men with hyperthyroid-
ism of non-autoimmune hyperthyroidism in desire, 
erectile function, and orgasmic function. The obtained 
results suggest that overt hyperthyroidism, particularly 
resulting from Graves’ disease, impairs male sexual 
functioning and may lead to a worsening of mood.
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